Rigosertib Completed Phase 2 Trials for Myelodysplastic Syndromes / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01326377ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)